Compare CTKB & BDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTKB | BDN |
|---|---|---|
| Founded | 1990 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.2M | 521.1M |
| IPO Year | 2021 | 1995 |
| Metric | CTKB | BDN |
|---|---|---|
| Price | $4.20 | $3.12 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 4 |
| Target Price | ★ $5.63 | $3.50 |
| AVG Volume (30 Days) | 976.1K | ★ 1.4M |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 10.67% |
| EPS Growth | N/A | ★ 9.65 |
| EPS | ★ N/A | N/A |
| Revenue | $193,015,000.00 | ★ $484,454,000.00 |
| Revenue This Year | $5.42 | $12.96 |
| Revenue Next Year | $7.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.67 | N/A |
| 52 Week Low | $2.62 | $2.47 |
| 52 Week High | $6.18 | $4.63 |
| Indicator | CTKB | BDN |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 61.23 |
| Support Level | $4.13 | $2.89 |
| Resistance Level | $4.29 | $3.15 |
| Average True Range (ATR) | 0.27 | 0.08 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 68.83 | 86.00 |
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.